Speedy CAR-T cells take on Hard-to-Treat myeloma in first human test
NCT ID NCT06698744
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 19 times
Summary
This early-phase study tests a new CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a person's own immune cells, which are modified in a shorter process than standard CAR-Ts and given as a one-time infusion after chemotherapy. The main goal is to check safety and find the right dose, with 12 adults taking part and follow-up lasting up to 15 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.